CLAIMS

1. A DNase 1-like 3 (D1L3) variant for use in the treatment of diseases or conditions characterized by the presence or accumulation of neutrophil extracellular traps (NETs), wherein the D1L3 variant comprises an amino acid sequence that has at least 90% sequence identity to the mature enzyme defined by residues 21 to 305 of SEQ ID NO: 2, with the proviso that the D1L3 variant has a deletion of all or part of the C- terminal tail defined by SEQ ID NO: 33.

2. The D1L3 variant for the use of claim 1, wherein the D1L3 variant is fused to a half-life extending moiety, wherein the half-life extending moiety is selected from the group consisting of albumin, transferrin, an Fc, or an elastin-like protein.

3. The D1L3 variant for the use of claim 1, wherein the D1L3 variant is fused to albumin.

4. The D1L3 variant for the use of claim 1, wherein the variant comprises an inactivated nuclear localization signal (NLS).

5. The D1L3 variant for the use of claim 4, wherein an NLS is inactivated by deletion of all or part of NLS1 and/or NLS2 of SEQ ID NO: 2, wherein NLS1 comprises amino acids 35-51 of SEQ ID NO: 2 and NLS2 comprises amino acids 296-305 of SEQ ID NO. 2.

6. The D1L3 variant for the use of claim 1, comprising deletion of all of the C- terminal tail defined by SEQ ID NO: 33.

7. The D1L3 variant for the use of any one of claims 1 to 6, wherein the disease or condition to be treated is a chronic or acute inflammatory disorder.

8. The D1L3 variant for the use of claim 7, wherein the disease or condition to be treated is an acute or chronic infection.

9. The D1L3 variant for the use of any one of claims 1 to 8, wherein the disease or condition to be treated is a vascular occlusion comprising NETs.

10. The D1L3 variant for the use of any one of claims 1 to 8, wherein the disease or condition to be treated is chronic neutrophilia, neutrophil aggregation and leukostasis, thrombosis and vascular occlusion, ischemia-reperfusion injury, surgical and traumatic tissue injury, an acute or chronic inflammatory reaction or disease, an autoimmune disease, cardiovascular disease,

metabolic disease, systemic inflammation, inflammatory disease of the respiratory tract, renal inflammatory diseases, inflammatory diseases related to transplanted tissue, and cancer.

11. The D1L3 variant for the use of any one of claims 1 to 10, wherein the D1L3 variant is to be administered intravenously, intraarterially, intraarticularly, intramuscularly, subcutaneously, topically, or by pulmonary administration.

12. The D1L3 variant for the use of any one of claims 1 to 6, wherein the subject has or is at risk of a ductal occlusion in a ductal system.

13. The D1L3 variant for the use of claim 12, wherein the ductal system is bile duct, tear duct, lactiferous duct, cystic duct, hepatic duct, ejaculatory duct, parotid duct, submandicular duct, major sublingual duct, Bartholin's duct, cerebral aqueduct, pancreas, mammary gland, vas deferens, ureter, urinary bladder, gallbladder, and liver.

14. The D1L3 variant for the use of claim 13, wherein the disease or condition to be treated is pancreatitis, cholangitis, conjunctivitis, mastitis, dry eye disease, an obstruction of the vas deferens, or renal disease.

15. The D1L3 variant for the use of any one of claims 1 to 6, wherein the disease or condition to be treated is systemic lupus erythematosus (SLE).

16. The D1L3 variant for the use of any one of claims 1 to 6, wherein the treatment comprises the additional administration of a DNase1 or an enzyme having at least 90% sequence identity to the mature enzyme defined by L23 to K282 of SEQ ID NO: 1.